1Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran
3Department of Biochemistry, Faculty of Sciences, Payame Noor University, Tehran, Iran
4Department of Medical Biotechnology, School of Medicine, Babol University of Medical Sciences, Babol, Iran
5Department of Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
© 2021 Korea Disease Control and Prevention Agency.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ethics Approval
Not applicable.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Funding
None.
Availability of Data
All data generated or analyzed during this study are included in this published article. For other data, these may be requested through the corresponding author.
Authors’ contributions
Conceptualization: MZ; Data curation: PH, SS, AR; Investigation: PH, SS; Supervision: MZ; Writing–original draft: SN, MM, FB; Writing–review & editing: MZ, PH.
Additional Contributions
The images that constitute Figure 1 were provided by Milad Zandi (Tehran University of Medical Sciences, Tehran, Iran).
Virus | Receptor | Steps of the coronavirus life cycle | Lipid interactions | Endocytic pathway | References |
---|---|---|---|---|---|
CCoV serotype 2 | APN | Entry | Plasma membrane cholesterol | Unknown | [54,55] |
MHV | CEACAM1 | Entry | Lipid rafts | Clathrin-mediated endocytosis | [33,48,49] |
FCoV serotype 2 | APN | Entry | Cholesterol | Clathrin- and caveolae-independent pathway that depends strongly on dynamin | [33,54] |
PEDV | APN | Entry | Cholesterol, lipid rafts | Clathrin- and caveolae-mediated endocytosis pathways | [33,56] |
TGEV | APN | Entry | Cholesterol | The route of entry is not yet known in terms of which endocytosis pathway occurs (clathrin- or non-clathrin-dependent mechanism or both) | [57,58] |
IBV | Not recognized | Entry | Lipid rafts | Macropinocytosis | [45] |
HCoV-229E | APN | 1. Entry | 1. Cholesterol | Caveolae-dependent endocytic | [44,49,53,59] |
2. Replication | 2. LA and AA | ||||
HCoV-OC43 | HLA class I, sialic acids, Neu5,9 | Entry | Cholesterol | Caveolae- dependent endocytosis | [33,51] |
MERS-CoV | DPP4 or CD26 | Replication | LA and AA | Clathrin-mediated endocytosis | [51,53,60] |
SARS-CoV | ACE2 | Entry | Lipid rafts | Clathrin- and caveolae-independent mechanism; may involve a clathrin-mediated or clathrin-dependent mechanism | [46,50] |
CCoV, canine coronavirus; APN, aminopeptidase N; MHV, murine hepatitis virus; CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; FCoV, feline coronavirus; PEDV, porcine epidemic diarrhea virus; TGEV, transmissible gastroenteritis virus; IBV, infectious bronchitis virus; HCoV-229E, human coronavirus 229E; LA, linoleic acid; AA, arachidonic acid; HCoV-OC43, human coronavirus OC43; HLA, human leukocyte antigen; MERS-CoV, Middle East respiratory syndrome coronavirus; DPP4, dipeptidyl peptidase 4; SARS-CoV, severe acute respiratory syndrome coronavirus; ACE2, angiotensin-converting enzyme-2.
Virus | Receptor | Steps of the coronavirus life cycle | Lipid interactions | Endocytic pathway | References |
---|---|---|---|---|---|
CCoV serotype 2 | APN | Entry | Plasma membrane cholesterol | Unknown | [54,55] |
MHV | CEACAM1 | Entry | Lipid rafts | Clathrin-mediated endocytosis | [33,48,49] |
FCoV serotype 2 | APN | Entry | Cholesterol | Clathrin- and caveolae-independent pathway that depends strongly on dynamin | [33,54] |
PEDV | APN | Entry | Cholesterol, lipid rafts | Clathrin- and caveolae-mediated endocytosis pathways | [33,56] |
TGEV | APN | Entry | Cholesterol | The route of entry is not yet known in terms of which endocytosis pathway occurs (clathrin- or non-clathrin-dependent mechanism or both) | [57,58] |
IBV | Not recognized | Entry | Lipid rafts | Macropinocytosis | [45] |
HCoV-229E | APN | 1. Entry | 1. Cholesterol | Caveolae-dependent endocytic | [44,49,53,59] |
2. Replication | 2. LA and AA | ||||
HCoV-OC43 | HLA class I, sialic acids, Neu5,9 | Entry | Cholesterol | Caveolae- dependent endocytosis | [33,51] |
MERS-CoV | DPP4 or CD26 | Replication | LA and AA | Clathrin-mediated endocytosis | [51,53,60] |
SARS-CoV | ACE2 | Entry | Lipid rafts | Clathrin- and caveolae-independent mechanism; may involve a clathrin-mediated or clathrin-dependent mechanism | [46,50] |
CCoV, canine coronavirus; APN, aminopeptidase N; MHV, murine hepatitis virus; CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; FCoV, feline coronavirus; PEDV, porcine epidemic diarrhea virus; TGEV, transmissible gastroenteritis virus; IBV, infectious bronchitis virus; HCoV-229E, human coronavirus 229E; LA, linoleic acid; AA, arachidonic acid; HCoV-OC43, human coronavirus OC43; HLA, human leukocyte antigen; MERS-CoV, Middle East respiratory syndrome coronavirus; DPP4, dipeptidyl peptidase 4; SARS-CoV, severe acute respiratory syndrome coronavirus; ACE2, angiotensin-converting enzyme-2.